IMP1734

Phase 2

Eikon Therapeutics, Inc. (EIKN)

00%

What is LOA?

Phase 2

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

Upcoming Catalysts

What are catalysts?

Q2 '27

EIKNPhase 2$520M

IMP1734 Phase 2 Est. Readout

IMP1734• Advanced Solid Tumor156

Q2 2027~QConfirmed

CT.gov

00%

Competitive Landscape

6 competitors in Advanced Solid Tumor

Drug Information

Target Indication

Advanced Solid Tumor

Clinical Trial

NCT06253130

Last updated: 1/18/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Source: FDA Orange Book

Drug Science

Mechanism of action & safety profile

Developer

EIKN

Eikon Therapeutics, Inc.

Biological Products, (No Diagnostic Substances)•North America•NASDAQ

Related Pipeline

EIK1001Phase 3

Advanced Melanoma

Paclitaxel + CarboplatinPhase 3

Non Small Cell Lung Cancer (Squamous or Non Squamous)

EIK1004-001 (IMP1707-001)Phase 2

Advanced Solid Tumors

EIK1005Phase 2

Advanced Solid Tumors

BDB001Phase 2

Tumor, Solid

View full pipeline

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts